◆ TICKERBASE交互式视图 →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

首页全部股票 › VEEV · English version

Veeva Systems Inc Class A (VEEV)

来自官方财务报表的收入、利润与现金流历史。

Health Care · 华尔街(美国) · 最近更新: 2026-09-15

Veeva Systems Inc. 为北美、欧洲、亚太地区、中东、非洲和拉丁美洲的生命科学行业提供基于云的软件。该公司为制药和生物技术公司提供包括 Veeva Vault CRM 套件的 Veeva Commercial Cloud; Veeva Medical 提供跨多个渠道和地区的医疗内容来源; Veeva PromoMats,端到端内容和数字资产管理解决方案;以及 Veeva Crossix,一个制药品牌分析平台。它还提供Veeva数据云,例如Veeva OpenData,客户参考数据解决方案; Veeva Link,提供深度数据; Veeva Compass,其中包括去识别化的纵向患者数据; Veeva CRM Pulse 提供访问和多渠道参与指标。此外,该公司还提供由 Veeva 临床平台组成的 Veeva 开发云,可促进临床试验的执行; Veeva 临床数据管理帮助申办者和 CRO 设计和运行试验; Veeva Safety,统一系统和流程;提供监管信息管理功能的 Veeva RIM,以及生命科学和消费品行业使用的 Veeva Quality Cloud;和 Veeva 商业咨询服务。

机器翻译

关键数据

查看交互式图表与完整报表 → 估值模型 (DCF) →

年度利润表

利润表TTM → 2026-07-312026-01-312025-01-312024-01-312023-01-312022-01-312021-01-312020-01-312019-01-312018-01-312017-01-312016-01-312015-01-312014-01-312013-01-312012-01-312011-01-31
总收入$3.5B$3.2B$2.7B$2.4B$2.2B$1.9B$1.5B$1.1B$862M$691M$544M$409M$313M$210M$130M$61M$29M
毛利$2.6B$2.4B$2.0B$1.7B$1.5B$1.3B$1.1B$801M$617M$479M$370M$267M$198M$128M$73M$32M$17M
毛利率%74.9%75.5%74.5%71.4%71.7%72.8%72.1%72.5%71.5%69.4%68.1%65.2%63.1%60.7%56.0%52.6%57.7%
营业利润(EBIT)$1.0B$916M$691M$429M$459M$505M$378M$286M$223M$158M$121M$79M$70M$39M$30M$7M$5M
营业利润率%29.9%28.7%25.2%18.2%21.3%27.3%25.8%25.9%25.9%22.9%22.2%19.2%22.3%18.7%23.2%10.8%17.5%
净利$1.0B$909M$714M$526M$488M$427M$380M$301M$230M$151M$78M$54M$40M$24M$3M$4M$4M
净利润率 %29.3%28.4%26.0%22.2%22.6%23.1%25.9%27.3%26.7%21.9%14.3%13.3%12.9%11.2%2.7%6.9%13.4%
EBITDA$1.4B$1.2B$959M$621M$488M$505M$407M$306M$237M$179M$135M$87M$74M$42M$31M$7M$5M
每股收益(EPS)$6.09$5.44$4.32$3.22$3.00$2.63$2.36$1.90$1.47$0.98$0.53$0.38$0.28$0.17$0.03$0.03$0.03
已发行股数 (M)165M167M165M163M162M162M161M158M156M154M148M145M144M138M126M126M126M

来源:公司公开报告(SEC)。在依赖任何数字前请核对 SEC EDGAR。

资产负债表、现金流、季度数据与完整财务比率见 VEEV 交互式查看器。 /companies/us/VEEV

类似公司

本网站信息仅用于教育与参考,不构成投资建议。不发布目标价或买卖建议。

English version →全部股票

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.